SuperGen announces Dacogen licensing

By Elaine Rigoli

Tampa, Fla., July 6 - SuperGen, Inc. announced the achievement of a milestone as a result of the licensing of Dacogen (decitabine) for injection by MGI Pharma to Cilag GmbH, a Johnson & Johnson company, granting exclusive development and commercialization rights in all territories outside North America.

Dacogen is a treatment for patients with myelodysplastic syndromes, which occur when there is a defect in the blood-forming stem cells, resulting in too few and poorly functioning blood cells.

SuperGen said it will receive 50% of the $10 million upfront payment and as a result of both the original agreement with MGI Pharma and this sublicense with Cilag up to $23.75 million in future milestone payments as they are achieved for Dacogen globally.

Additionally, SuperGen will receive the 20% to 30% royalty on all sales worldwide.

MGI Pharma and the Janssen-Cilag companies will jointly implement a strategic plan for the global clinical development of Dacogen.

Under this agreement, MGI Pharma will retain all commercialization rights to Dacogen in North America. Janssen-Cilag companies will be responsible for conducting regulatory and commercial activities related to Dacogen in all territories outside North America, while MGI Pharma retains all responsibility for all activities in the United States, Canada and Mexico.

SuperGen is a pharmaceutical company based in Dublin, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.